Australia’s Health Technology Assessment system uses comparative evaluation to determine the value of medicines against a relevant comparator. Comparator selection has increasingly defaulted to the lowest cost comparator. This analysis finds that the lowest cost comparator use has become systemic, creating structural barriers to patient access. It provides a phased roadmap proposing eight actions.

Antimicrobial resistance is a critical global health challenge, threatening the effectiveness of modern medicine and increasing the risk of untreatable infections. This report summarises discussion at the 2024 Antimicrobial Subscription Model roundtable. The roundtable agreed on 10 key principles to guide the development of a pilot program for novel antimicrobials and its implementation in Australia.

Hypophosphatasia (HPP) is a genetic, multisystem condition that impairs the body’s ability to properly mineralise bones and teeth. Through the lens of HPP, this report illustrates how Australia’s healthcare system remains unfit for people with rare diseases. It presents a clear case for targeted, achievable reforms to improve diagnosis, treatment access and care coordination for...

Alzheimer’s disease is one of the most significant health challenges of our time, with the potential to impact millions of Australians and place a substantial strain on our health and aged care systems. This report proposes seven recommendations to achieve a future where Australians with Alzheimer’s disease live with dignity, supported by compassionate and comprehensive...

This report argues that radioligand therapy (RLT) advancements are set to support the next phase in cancer care with its precision medicine approach. RLT uses radioactive molecules to kill cancer cells, sparing healthy tissue and limiting patient side effects.